WebSep 4, 2015 · When a person decides to have statin therapy, a statin of high intensity and low cost should be offered. Atorvastatin 20 mg is recommended as the preferred initial … WebBefore initiation of statin treatment, creatine kinase concentration should be measured in patients who have had persistent, generalised, unexplained muscle pain (whether associated or not with previous lipid-regulating drugs); if the baseline concentration is more than 5 times the upper limit of normal (ULN), a repeat measurement should be taken …
Scenario: Lipid therapy - secondary prevention of CVD - NICE
WebHigh-intensity statin therapy (atorvastatin 40–80 mg or rosuvastatin 20–40 mg) is recommended for most of these patients, and moderate-intensity statins for the remaining groups. 17 The new 2013 ACC/AHA guidelines match statin assignment to total plaque burden better than the older guidelines, with only a modest increase in the number of ... WebRosuvastatin and simvastatin — manufacturers advise to adjust dose of the statin. Fusidic acid — the Medicines and Healthcare products Regulatory Agency (MHRA) advises that … biometry book
Hyperlipidemia: Drugs for Cardiovascular Risk Reduction in Adults
WebNov 15, 2024 · NICE CG181 recommends that those with a 10-year risk of an ASCVD event greater than 10% should be offered atorvastatin 20 mg per day to lower their CVD risk. By contrast, patients with established ASCVD, whose risk of (recurrent) events is higher, should commence 80 mg of atorvastatin per day. WebMay 4, 2024 · Refer to the lipid management algorithm and related NICE guidelines (CG71, CG181) for guidance on initiation, titration, and monitoring of statin therapy. Statin Intolerance Pathway Algorithm 1: Statin Intolerance Pathway Definition of Statin Intolerance. Intolerance to initial statin therapy is defined by NICE as the presence of clinically ... WebAug 3, 2024 · Therapeutic Recommendations Maximally tolerated statins have been recommended as the most optimal low-density lipoprotein cholesterol (LDL-C) risk-based therapy for patients with clinical ASCVD and persistent hypertriglyceridemia (fasting triglycerides >150 and <500 mg/dL). biometry and statistics cornell